Ultragenyx Pharmaceutical Inc. has filed a Follow-on Equity Offering in the amount of $175 million and completed a Follow-on Equity Offering in the amount of $250.000005 million. Ultragenyx may use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products, or assets, though we currently have no specific agreements, commitments, or understandings with respect to any in-licensing or acquisitions. Finally, we may use any remaining proceeds for working capital and other general corporate purposes.